Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
127.88
+4.04 (3.26%)
At close: Jun 26, 2026, 4:00 PM EDT
127.20
-0.68 (-0.53%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Gilead Sciences Employees
Gilead Sciences had 17,000 employees as of December 31, 2025. The number of employees decreased by 600 or -3.41% compared to the previous year.
Employees
17,000
Change (1Y)
-600
Growth (1Y)
-3.41%
Revenue / Employee
$1,749,176
Profits / Employee
$542,118
Market Cap
158.77B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17,000 | -600 | -3.41% |
| Dec 31, 2024 | 17,600 | -400 | -2.22% |
| Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
| Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
| Dec 31, 2021 | 14,400 | 800 | 5.88% |
| Dec 31, 2020 | 13,600 | 2,600 | 23.64% |
| Jan 31, 2019 | 11,000 | 1,000 | 10.00% |
| Jan 31, 2018 | 10,000 | 1,000 | 11.11% |
| Jan 31, 2017 | 9,000 | 1,000 | 12.50% |
| Jan 31, 2016 | 8,000 | 1,000 | 14.29% |
| Jan 31, 2015 | 7,000 | 900 | 14.75% |
| Jan 31, 2014 | 6,100 | 1,100 | 22.00% |
| Jan 31, 2013 | 5,000 | 500 | 11.11% |
| Jan 31, 2012 | 4,500 | 500 | 12.50% |
| Jan 31, 2011 | 4,000 | 148 | 3.84% |
| Jan 31, 2010 | 3,852 | 411 | 11.94% |
| Jan 31, 2009 | 3,441 | 462 | 15.51% |
| Jan 31, 2008 | 2,979 | 464 | 18.45% |
| Jan 31, 2007 | 2,515 | 615 | 32.37% |
| Jan 31, 2006 | 1,900 | 246 | 14.87% |
| Feb 28, 2005 | 1,654 | 229 | 16.07% |
| Feb 27, 2004 | 1,425 | 175 | 14.00% |
| Feb 28, 2003 | 1,250 | 250 | 25.00% |
| Feb 28, 2002 | 1,000 | 150 | 17.65% |
| Feb 28, 2001 | 850 | 90 | 11.84% |
| Dec 31, 1999 | 760 | 467 | 159.39% |
| Dec 31, 1998 | 293 | 4 | 1.38% |
| Dec 31, 1997 | 289 | 41 | 16.53% |
| Dec 31, 1996 | 248 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
GILD News
- 1 day ago - Merck says FDA approves Keytruda and Keytruda Qlex in combo with Trodelvy - TheFly
- 2 days ago - U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer - Business Wire
- 2 days ago - For decades, the only first treatment for one of the deadliest breast cancers was standard chemotherapy. Now there are two newly approved drugs. - WSJ
- 2 days ago - FDA approves Gilead’s Trodelvy for two indications - TheFly
- 3 days ago - Gilead announces EC grants marketing authorization for Trodelvy - TheFly
- 3 days ago - European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors - Business Wire
- 9 days ago - The Healthcare M&A Wave - Forbes
- 11 days ago - Gilead announces FDA approval of sNDA for Yeztugo - TheFly